Impact of visceral pleural invasion on the survival of patients with non-small cell lung cancer

Kudo, Yujin; Saji, Hisashi; Shimada, Yoshihisa; Nomura, Masatoshi; Matsubayashi, Jun; Nagao, Toshitaka; Kakihana, Masatoshi; Usuda, Jitsuo; Kajiwara, Naohiro; Ohira, Tetsuya; Ikeda, Norihiko

doi:10.1016/j.lungcan.2012.08.004

Cited by 82 publications

(64 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,13) Various factors such as age, sex, smoking habit, ethnicity, tumor size, SUVmax, visceral pleural invasion, lymphatic invasion, and venous invasion have been reported to predict survival in surgical cases of NSCLC. [14][15][16][17][18][19][20][21][22][23][24][25] However, only a few reports have analyzed AD and SQ separately. In the present study, the most powerful prognostic factors for RFS and OS in AD were histologic pleural invasion.…”

Section: Discussionmentioning

confidence: 99%

Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma

Nakamura

Sakai

Kimura

et al. 2017

ATCS

Self Cite

View full text Add to dashboard Cite

IntroductionLung adenocarcinoma (AD) and squamous cell carcinoma (SQ) are the two major histologic types of nonsmall-cell lung cancer (NSCLC), and have been considered to be almost similar in both postsurgical prognosis and chemotherapeutic responses for a long period of time. However, recent multiple studies on the postsurgical outcomes of these two histologic types Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell CarcinomaHaruhiko Nakamura, MD, PhD, Hiroki Sakai, MD, Hiroyuki Kimura, MD, Tomoyuki Miyazawa, MD, Hideki Marushima, MD, PhD, and Hisashi Saji, MD, PhD Purpose: The aim of this study was to compare the clinicopathologic prognostic factors between patients who underwent lung resection for adenocarcinoma (AD) and those with squamous cell carcinoma (SQ). Methods: A database of patients with lung AD or SQ who underwent surgery with curative intent in our department from January 2008 to December 2014 was reviewed. Associations between various clinicopathologic factors, postsurgical recurrence-free survival (RFS), and overall survival (OS) were analyzed to find significant prognostic factors. Results: A total of 537 lung cancer patients (AD, 434; SQ, 103) were included in this study. Although RFS was similar in patients with AD and SQ, OS was significantly poorer in those with SQ. Multivariate analysis in patients with AD revealed that age (≥69 vs. <69), lymphatic invasion, and histologic pleural invasion (p0 vs. p1-3) were associated with RFS, while gender and pleural invasion were associated with OS. In SQ, however, smoking, clinical stage, and pulmonary metastasis were associated with RFS in the multivariate analysis. Conclusion: Since significant postoperative prognostic factors are quite different between lung AD and SQ, these two histologic types should be differently analyzed in a clinical study.

show abstract

Section: Discussionmentioning

confidence: 99%

Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma

Nakamura

Sakai

Kimura

et al. 2017

ATCS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients who underwent wedge resection tended to have PL1/2 more often than other patients ( P 5 .053); most of the patients who underwent wedge resection did so because of peripheral tumors. The risk of recurrence was higher among patients who underwent 16 Li et al 32 Kudo et al 33 Maeda et al 29 Maeda Dr Travis: contributed to study design; data analysis and interpretation; drafting and review of the manuscript for important intellectual content; and final approval of the version to be published. Dr Adusumilli: contributed to study concept and design; data acquisition, analysis, and interpretation; drafting and review of the manuscript for important intellectual content; and fi nal approval of the version to be published.…”

Section: Acknowledgmentsmentioning

confidence: 99%

Visceral Pleural Invasion Does Not Affect Recurrence or Overall Survival Among Patients With Lung Adenocarcinoma ≤ 2 cm

Nitadori

Colovos

Kadota

et al. 2013

Chest

View full text Add to dashboard Cite

Lung cancer is the second most common cancer and is the primary cause of cancer-related death in both men and women in the United States. 1 Currently, 80% of patients with lung cancer are given a diagnosis of primary non-small cell lung cancer (NSCLC). The most common form of NSCLC is adenocarcinoma (ADC). 2,3 Advances in imaging technology and recommendations to screen high-risk patients with CT scan have increased the probability of detecting small, early stage lung ADC. 4 The most effective treatment of early stage lung ADC is surgical resection; however, the reported 5-year survival rates for patients with stage I disease range from 60% to 90% after complete resection. [5][6][7][8][9] Prognosis for patients with lung ADC is best characterized by the seventh edition of the Union for International Cancer Control/American Joint Committee on Cancer TNM staging classification. 10 For T stage, tumor size has been found to have prognostic signifi cance, and its analysis has led to recommendations to subclassify small tumors ( Յ 3 cm) into two subsets: T1a ( Յ 2 cm) and T1b ( . 2 cm and Յ 3 cm [2-3 cm]). In addition, visceral pleural invasion (VPI) is known to be a factor of poor prognosis, [11][12][13][14][15][16][17] and the presence of VPI upstages the T stage from T1 to T2. [18][19][20] Because most studies focused on overall survival (OS) and the natural history of early stage tumors is better refl ected by the cumulative incidence of recurrence (CIR), the clinical signifi cance of VPI in these small, early stage tumors is poorly defi ned. The goal of the present study was to reevaluate the

show abstract

“…Therefore, it has been an important issue to identify and validate the molecular prognostic factors affecting recurrence and survival in lung adenocarcinoma patients, especially in those with early stage disease. In this context, various clinicopathologic factors have been investigated (Kudo et al , 2012; Arrieta Rodriguez et al , 2013; Brueckl et al , 2013; Chen et al , 2013; Kawase et al , 2013; Kwon et al , 2013; Nentwich et al , 2013; Sun et al , 2013; Kim et al , 2013a). Although the key genetic alterations have been largely revealed in lung adenocarcinoma (Imielinski et al , 2012), the useful molecular prognostic factors contributing to or accelerating the carcinogenic process, disease progression, or recurrence have not yet been fully understood, especially in stage I disease (Woo et al , 2012; Shimizu et al , 2013).…”

mentioning

confidence: 99%

Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas

Yuan

Kim

et al. 2014

Br J Cancer

View full text Add to dashboard Cite

Background:c-MYC copy number gain (c-MYC gain) has been associated with aggressive behaviour in several cancers. However, the role of c-MYC gain has not yet been determined in lung adenocarcinomas classified by genetic alterations in epidermal growth factor receptor (EGFR), KRAS, and anaplastic lymphoma kinase (ALK) genes. We investigated the clinicopathologic and prognostic significance of c-MYC gain for disease-free survival (DFS) and overall survival (OS) according to EGFR, KRAS, and ALK gene status and stages in lung adenocarcinomas.Methods:In 255 adenocarcinomas resected in Seoul National University Bundang Hospital from 2003 to 2009, fluorescence in situ hybridisation (FISH) with c-MYC probe and centromeric enumeration probe 8 (CEP8) was analysed using tissue microarray containing single representative core per each case. EGFR (codon 18 to 21) and KRAS (codon 12, 13, and 61) mutations were analysed by polymerase chain reaction and direct sequencing method from formalin-fixed, paraffin-embedded tissue sections. ALK rearrangement was determined by FISH method. c-MYC gain was defined as >2 copies per nucleus, chromosome 8 gain as ⩾3 copies per nucleus, and gain of c-MYC:CEP8 ratio (hereafter, c-MYC amplification) as ⩾2.Results:We observed c-MYC gain in 20% (51 out of 255), chromosome 8 gain in 5.5% (14 out of 255), c-MYC amplification in 2.4% (6 out of 255), EGFR mutation in 49.4% (118 out of 239), KRAS mutation in 5.7% (7 out of 123), and ALK rearrangement in 4.9% (10 out of 205) of lung adenocarcinomas. c-MYC gain was observed in 19% (22 out of 118) of patients with lung adenocarcinomas with an EGFR mutation, but not in any patients with a KRAS mutation, or an ALK rearrangement. c-MYC gain (but not chromosome 8 gain or c-MYC amplification) was an independent poor-prognostic factor in the full cohort of lung adenocarcinoma (P=0.022, hazard ratio (HR)=1.71, 95% confidence interval (CI), 1.08–2.69 for DFS; P=0.032, HR=2.04, 95% CI, 1.06–3.91 for OS), as well as in stage I subgroup (P=0.023, HR=4.70, 95% CI, 1.24–17.78 for DFS; P=0.031, HR=4.65, 95% CI, 1.15–18.81 for OS), and in EGFR-mutant subgroup (P=0.022; HR=2.14; 95% CI, 1.11–4.10 for DFS).Conclusions:c-MYC gain (but not chromosome 8 gain or c-MYC amplification) was an independent poor-prognostic factor for DFS and OS in lung adenocarcinomas, both in full cohort and stage I cancer, and possibly for DFS in EGFR-mutant adenocarcinomas. Additional studies are required to determine if patients with lung adenocarcinoma with c-MYC gain are candidates for additional first-line treatment to mitigate their increased risk for disease progression and death.

show abstract

Impact of visceral pleural invasion on the survival of patients with non-small cell lung cancer

Cited by 82 publications

References 28 publications

Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma

Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma

Visceral Pleural Invasion Does Not Affect Recurrence or Overall Survival Among Patients With Lung Adenocarcinoma ≤ 2 cm

Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas

Contact Info

Product

Resources

About